Key Highlights

  • Chrysos reported FY26 Revenue of $88.1 million, up 33% from $66.1 million in FY25.
  • FY26 EBITDA increased 68% to $27.2 million, while the EBITDA Margin rose to 31% from 24%.
  • PhotonAssay sample volumes reached 11.3 million during FY26, representing a 67% increase from the previous year.
  • Chrysos expects FY27 revenue of $108 million to $118 million and EBITDA of $35 million to $42 million.

Chrysos Corporation Ltd (ASX:C79) shares were trading at $7.52, up 16.59%, at the time of writing on 11 August 2026, after the company released its FY26 financial and operational update. The company reported record annual revenue and EBITDA, alongside increased PhotonAssay utilisation and further expansion of its contracted fleet.

Chrysos said total revenue reached $88.1 million in FY26, compared with $66.1 million a year earlier. EBITDA rose to $27.2 million from $16.1 million, while the EBITDA margin increased from 24% to 31%.

PhotonAssay Volumes Reach New Record

The company reported continued growth in sample processing through its PhotonAssay technology. Total samples processed during FY26 reached 11.3 million, an increase of 67% from FY25.

Monthly volumes exceeded one million samples for five consecutive months from March 2026. July subsequently recorded more than 1.1 million samples, according to the company.

The increase in sample volumes also contributed to higher Additional Assay Charges, which reached $25.5 million during FY26, compared with $10.1 million in FY25. These charges represented 29% of total revenue, compared with 15% in the previous financial year.

Minimum Monthly Assay Payments increased to $62.5 million from $55.9 million, reflecting the expansion of the deployed PhotonAssay fleet.

Contracted Fleet Continues to Expand

Chrysos signed 24 new Lease agreements during FY26, taking its contracted units to 83. Four additional agreements signed after the reporting period increased the contracted total to 87.

Seven units were deployed during FY26 across Canada, Australia and Chile, while six additional units were in the deployment process at the time of the announcement.

The company also reported expansion across its laboratory relationships, including deployments involving ALS, SGS, Bureau Veritas, MSA and Intertek. Chrysos said its technology now has units deployed with all four major laboratory companies.

Direct-to-Mine Deployments Add to Customer Base

Chrysos continued to expand its direct-to-mine leasing strategy during FY26. Agreements included deployments involving Newmont's Merian mine in Suriname, Acrux Gold's Cononish Project in Scotland, Alkane's Björkdal mine in Sweden, Pantoro's Norseman mine in Australia and Allied Gold operations in West Africa and Ethiopia.

The company also highlighted its first deployment to South America through Bureau Veritas in Chile. Further agreements involving Bureau Veritas were signed for Peru and Mexico after the FY26 reporting period.

Cash Flow and Funding Capacity Improve

Chrysos generated $17.9 million in net operating cash inflow during FY26, compared with $8.8 million in FY25.

At the end of the period, the company reported $25.9 million in cash and $140 million of undrawn Debt capacity. During FY26, Chrysos refinanced its corporate facilities through a new three-year $200 million syndicated debt Facility provided by ANZ, National Australia Bank and Export Finance Australia.

The new facility replaced the company's previous asset-based financing structure and provided additional funding headroom, according to the announcement.

FY27 Revenue and EBITDA Guidance

For FY27, Chrysos expects revenue between $108 million and $118 million and EBITDA between $35 million and $42 million. The guidance is based on constant-currency assumptions specified in the company's announcement.

Chrysos said its FY27 operating plans include a Manufacturing cadence of 18 units per year. The company also expects contracted units to progressively become deployed, revenue-generating Assets , while utilisation across the existing fleet remains an important component of its revenue model.

The company further noted that it is expanding the potential application of PhotonAssay beyond gold to other commodities, including silver and copper.

Conclusion

Chrysos enters FY27 following a year in which revenue, EBITDA, sample volumes and Operating Cash Flow all increased from FY25 levels. The company also expanded its contracted fleet, added deployments across major laboratory customers and increased its direct-to-mine presence. Its FY27 guidance calls for revenue of $108 million to $118 million and EBITDA of $35 million to $42 million, while the strengthened debt facility provides additional funding capacity for manufacturing and deployment activities. The company's next phase will be shaped by the conversion of contracted units into deployed assets and the utilisation of its growing installed base.